MYUNGMOON PharmLtd Past Earnings Performance
Past criteria checks 0/6
MYUNGMOON PharmLtd has been growing earnings at an average annual rate of 40.1%, while the Pharmaceuticals industry saw earnings growing at 10.9% annually. Revenues have been growing at an average rate of 4.2% per year.
Key information
40.1%
Earnings growth rate
44.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 4.2% |
| Return on equity | -9.6% |
| Net Margin | -4.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
MYUNGMOON Pharm co.,Ltd's (KRX:017180) 35% Share Price Surge Not Quite Adding Up
Jul 26
MYUNGMOON PharmLtd (KRX:017180) Has No Shortage Of Debt
Mar 21Does MYUNGMOON PharmLtd (KRX:017180) Have A Healthy Balance Sheet?
Mar 31Introducing MYUNGMOON PharmLtd (KRX:017180), A Stock That Climbed 77% In The Last Five Years
Feb 06
Does Myungmoon Pharm (KRX:017180) Have A Healthy Balance Sheet?
Dec 15Revenue & Expenses Breakdown
How MYUNGMOON PharmLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 176,368 | -7,719 | 97,200 | 2,648 |
| 31 Mar 24 | 173,796 | -6,322 | 93,318 | 3,306 |
| 31 Dec 23 | 169,567 | -4,525 | 88,779 | 2,970 |
| 30 Sep 23 | 166,698 | 4,140 | 81,190 | 2,686 |
| 30 Jun 23 | 160,366 | 5,172 | 74,989 | 2,450 |
| 31 Mar 23 | 157,638 | 7,485 | 71,548 | 1,952 |
| 31 Dec 22 | 152,135 | 7,868 | 67,202 | 1,711 |
| 30 Sep 22 | 147,514 | -4,770 | 72,950 | 1,351 |
| 30 Jun 22 | 145,836 | -4,998 | 71,380 | 1,530 |
| 31 Mar 22 | 140,778 | -6,517 | 65,912 | 2,367 |
| 31 Dec 21 | 137,760 | -6,865 | 63,239 | 2,065 |
| 30 Sep 21 | 134,608 | -6,830 | 61,097 | 2,093 |
| 30 Jun 21 | 131,560 | -11,501 | 62,214 | 1,600 |
| 31 Mar 21 | 125,543 | -21,751 | 67,788 | 219 |
| 31 Dec 20 | 127,853 | -27,639 | 67,803 | 535 |
| 30 Sep 20 | 134,148 | -32,042 | 70,770 | 623 |
| 30 Jun 20 | 141,691 | -28,654 | 73,730 | 623 |
| 31 Mar 20 | 146,936 | -24,325 | 73,789 | 878 |
| 31 Dec 19 | 149,346 | -20,402 | 74,570 | 676 |
| 30 Sep 19 | 152,571 | -7,612 | 66,886 | 637 |
| 30 Jun 19 | 147,467 | -6,687 | 65,432 | 637 |
| 31 Mar 19 | 149,139 | -945 | 62,783 | 252 |
| 31 Dec 18 | 147,499 | 988 | 61,369 | 141 |
| 30 Sep 18 | 142,334 | 1,569 | 62,759 | 0 |
| 30 Jun 18 | 142,469 | 2,414 | 61,961 | 0 |
| 31 Mar 18 | 142,600 | 7,672 | 63,060 | 0 |
| 31 Dec 17 | 140,138 | 7,807 | 63,106 | 0 |
| 30 Sep 17 | 139,509 | 7,688 | 61,806 | 0 |
| 30 Jun 17 | 141,974 | 8,471 | 62,358 | 0 |
| 31 Mar 17 | 140,917 | 5,206 | 59,122 | 0 |
| 31 Dec 16 | 142,180 | 6,746 | 58,728 | 0 |
| 30 Sep 16 | 138,775 | -9,119 | 60,899 | 5 |
| 30 Jun 16 | 135,216 | -9,085 | 58,222 | 5 |
| 31 Mar 16 | 130,907 | -13,359 | 57,710 | 19 |
| 31 Dec 15 | 125,101 | -16,135 | 57,254 | 24 |
| 30 Sep 15 | 121,032 | -873 | 51,767 | 19 |
| 30 Jun 15 | 114,633 | -2,147 | 49,566 | 19 |
| 31 Mar 15 | 108,932 | 201 | 46,130 | 5 |
| 31 Dec 14 | 105,421 | 761 | 44,049 | 8 |
| 30 Sep 14 | 101,790 | 346 | 42,273 | 72 |
| 30 Jun 14 | 100,199 | 33 | 41,230 | 72 |
| 31 Mar 14 | 101,352 | 443 | 41,608 | 96 |
| 31 Dec 13 | 103,723 | 1,026 | 40,863 | 101 |
| 30 Sep 13 | 105,079 | -834 | 42,061 | 386 |
Quality Earnings: A017180 is currently unprofitable.
Growing Profit Margin: A017180 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A017180 is unprofitable, but has reduced losses over the past 5 years at a rate of 40.1% per year.
Accelerating Growth: Unable to compare A017180's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A017180 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.9%).
Return on Equity
High ROE: A017180 has a negative Return on Equity (-9.62%), as it is currently unprofitable.